My guess is that the venue they are referring to is ASCO. This does not mean that the FDA is not already aware of the results today and at anytime will not recommend an immediate advancement of Kevetrin into a phase 2 or 3 for ovarian or pancreatic or another hard to treat cancer - of course that is major speculation on my part.
Market Data 
Markets 
AI
